{"doi":"10.1158/2159-8290.cd-nb2015-058","title":"Nivolumab + Ipilimumab Ups Melanoma Response","abstract":"<jats:title>Abstract</jats:title>\n               <jats:p>For patients with advanced melanoma, the combination of ipilimumab and nivolumab yields better responses than ipilimumab alone. However, the two-drug combination is much more likely to cause side effects than the monotherapy.</jats:p>","journal":"Cancer Discovery","year":2015,"id":627850,"datarank":0.14490897142113113,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.040936894337139304,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.040936894337139304,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":1,"citers_with_citation_signal":1,"citers_with_endowment":1,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Nivolumab + Ipilimumab Ups Melanoma Response","abstract":"<jats:title>Abstract</jats:title>\n               <jats:p>For patients with advanced melanoma, the combination of ipilimumab and nivolumab yields better responses than ipilimumab alone. However, the two-drug combination is much more likely to cause side effects than the monotherapy.</jats:p>","is_dataset_classified":null,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"25898833","pmcid":null,"openalex_id":"https://openalex.org/W4241093956","authors":[],"funders":[],"total_grants":0,"fwci":0.1311,"citation_percentile":0.56210667,"influential_citations":0,"citation_trend":[{"year":2015,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://aacrjournals.org/cancerdiscovery/article/5/6/OF2/4981/Nivolumab-Ipilimumab-Ups-Melanoma","host_type":"publisher"},{"url":"https://doi.org/10.1158/2159-8290.cd-nb2015-058","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/25898833","host_type":"repository"}],"fields_of_study":["Cancer Immunotherapy and Biomarkers","CAR-T cell therapy research","Immunotherapy and Immune Responses","Antibodies, Monoclonal","Antineoplastic Combined Chemotherapy Protocols","Female","Humans","Male","Melanoma"],"mesh_terms":["Antibodies, Monoclonal","Antineoplastic Combined Chemotherapy Protocols","Female","Humans","Male","Melanoma"],"keywords":["Ipilimumab","Nivolumab","Melanoma","Medicine","Metastatic melanoma","Oncology","Drug","Internal medicine","Pharmacology","Cancer research","Cancer","Immunotherapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T00:10:48.983910Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}